The purpose of this multicenter study was to evaluate Multiplicom's BRCA MASTR Dx kit to detect clinically important variants in BRCA1 and BRCA2 in FFT derived ovarian and breast tumor samples. This evidence concerns the gene BRCA2 and breast neoplasm.